Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study demonstrates the bioequivalence of DA-1229_01(A) at Fasting State when compared with Sugamet sustained-release(SR) Tab 5/1000mg® in healthy adults
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test drug, Reference drug group | Experimental | Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar. The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar. |
|
| Reference drug,Test drug group | Active Comparator | Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar. The wash-out for fasting study is 14 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DA-1229_01(A), Sugamet SR Tab 5/1000mg® | Drug | Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar. The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar. |
| Measure | Description | Time Frame |
|---|---|---|
| Area under the concentration-time curve(AUCt) | AUCt of evogliptin and metformin | Hour -1 ~ Hour 72 |
| Maximum plasmaconcentration of drug in plasma(Cmax) | Cmax of evogliptin and metformin | Hour -1 ~ Hour 72 |
| Measure | Description | Time Frame |
|---|---|---|
| Area under the plasma drug concentration-time curve from time 0 to infinity(AUCinf) | AUCinf of evogliptin and metformin | Hour -1 ~ Hour 72 |
| AUCt/AUCinf | AUCt/AUCinf of evogliptin and metformin |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sung Dae Kwon, M.D., Ph.D. | Metro Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Metro Hospital | Anyang-si | Gyeonggi-do | 14096 | South Korea |
Not provided
| ID | Term |
|---|---|
| D004341 | Drug Evaluation |
| ID | Term |
|---|---|
| D000076722 | Drug Development |
| D008919 | Investigative Techniques |
| D005069 | Evaluation Studies as Topic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Sugamet SR Tab 5/1000mg®, DA-1229_01(A) | Drug | Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar. The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar. |
|
|
| Hour -1 ~ Hour 72 |
| Time to reach the maximum plasma concentration(Tmax) | Tmax of evogliptin and metformin | Hour -1 ~ Hour 72 |
| Terminal elimination rate constant(ramda z) | ramda z of evogliptin and metformin | Hour -1 ~ Hour 72 |
| Terminal elimination half-life(t1/2) | t1/2 of evogliptin and metformin | Hour -1 ~ Hour 72 |